<br />
EUROPEAN MEDICAL JOURNAL<br />
ISSN 2397-6764 Vol 1.2 • April 2016 • emjreviews.com<br />
CONTENTS<br />
EDITORIAL BOARD......................................................................................................................................... 4<br />
FEATURES<br />
• HOW I TREAT: LUNG CANCER................................................................................................................ 12<br />
Dr Antonio Rossi<br />
• BIG DATA AND CARDIOLOGY: TIME FOR MASS ANALYTICS?....................................................... 15<br />
Dr Rahul Potluri et al.<br />
ABSTRACT AND POSTER SESSION REVIEW<br />
• REGORAFENIB IN ADVANCED AND REFRACTORY GASTROINTESTINAL CANCERS............. 18<br />
ARTICLES<br />
• EDITOR’S PICK: URGENT START PERITONEAL DIALYSIS: A VIABLE OPTION FOR ACUTE<br />
AND CHRONIC KIDNEY FAILURE.......................<a title="European Medical Journal 1.2 2016 page 1" href="http://viewer.zmags.com/publication/2e5dba2c?page=1"> EUROPEAN MEDICAL JOURNAL ISSN 2397-6764 </a>
<a title="European Medical Journal 1.2 2016 page 2" href="http://viewer.zmags.com/publication/2e5dba2c?page=2"> CONTENTS EDITORIAL BOARD.......................</a>
<a title="European Medical Journal 1.2 2016 page 3" href="http://viewer.zmags.com/publication/2e5dba2c?page=3"> EUROPEAN MEDICAL JOURNAL • THE ROLE OF GENDER I</a>
<a title="European Medical Journal 1.2 2016 page 4" href="http://viewer.zmags.com/publication/2e5dba2c?page=4"> Editorial Board Editor-in-Chief: Prof Markus P</a>
<a title="European Medical Journal 1.2 2016 page 5" href="http://viewer.zmags.com/publication/2e5dba2c?page=5"> European Medical Journal Prof Robert Dellaval</a>
<a title="European Medical Journal 1.2 2016 page 6" href="http://viewer.zmags.com/publication/2e5dba2c?page=6"> SUBSCRIBE TOTHEEMJ NEWSLETTER NwEwwW.newSs.eLmjEr</a>
<a title="European Medical Journal 1.2 2016 page 7" href="http://viewer.zmags.com/publication/2e5dba2c?page=7"> Welcome Hello and welcome to the second editio</a>
<a title="European Medical Journal 1.2 2016 page 8" href="http://viewer.zmags.com/publication/2e5dba2c?page=8"> If you are interested in submitting a paper to </a>
<a title="European Medical Journal 1.2 2016 page 9" href="http://viewer.zmags.com/publication/2e5dba2c?page=9"> Foreword </a>
<a title="European Medical Journal 1.2 2016 page 10" href="http://viewer.zmags.com/publication/2e5dba2c?page=10"> Available Now European Med</a>
<a title="European Medical Journal 1.2 2016 page 11" href="http://viewer.zmags.com/publication/2e5dba2c?page=11"> FEATURES How I Treat: Multiple Sclerosis • Prof</a>
<a title="European Medical Journal 1.2 2016 page 12" href="http://viewer.zmags.com/publication/2e5dba2c?page=12"> HOW I TREAT: LUNG CANCER *Antonio Rossi</a>
<a title="European Medical Journal 1.2 2016 page 13" href="http://viewer.zmags.com/publication/2e5dba2c?page=13"> ultimately relapse, for which salvage chemotherap</a>
<a title="European Medical Journal 1.2 2016 page 14" href="http://viewer.zmags.com/publication/2e5dba2c?page=14"> maintenance therapy with pemetrexed is the s</a>
<a title="European Medical Journal 1.2 2016 page 15" href="http://viewer.zmags.com/publication/2e5dba2c?page=15"> BIG DATA AND CARDIOLOGY: TIME FOR MASS ANALY</a>
<a title="European Medical Journal 1.2 2016 page 16" href="http://viewer.zmags.com/publication/2e5dba2c?page=16"> have already run into billions of dollars. It is </a>
<a title="European Medical Journal 1.2 2016 page 17" href="http://viewer.zmags.com/publication/2e5dba2c?page=17"> 6. Floderus B et al. Smoking and mortality: a 2</a>
<a title="European Medical Journal 1.2 2016 page 18" href="http://viewer.zmags.com/publication/2e5dba2c?page=18"> REGORAFENIB IN ADVANCED AND REFRACTORY </a>
<a title="European Medical Journal 1.2 2016 page 19" href="http://viewer.zmags.com/publication/2e5dba2c?page=19"> characterised by advanced disease, with 82% of pa</a>
<a title="European Medical Journal 1.2 2016 page 20" href="http://viewer.zmags.com/publication/2e5dba2c?page=20"> Table 1: Median progression-free survival (PFS) ±</a>
<a title="European Medical Journal 1.2 2016 page 21" href="http://viewer.zmags.com/publication/2e5dba2c?page=21"> in the early stages of treatment, may help</a>
<a title="European Medical Journal 1.2 2016 page 22" href="http://viewer.zmags.com/publication/2e5dba2c?page=22"> 0.77 (0.42–1.41) ITT 0.57 (0.30–1.06) IPE </a>
<a title="European Medical Journal 1.2 2016 page 23" href="http://viewer.zmags.com/publication/2e5dba2c?page=23"> regorafenib treatment cycle will be investigated </a>
<a title="European Medical Journal 1.2 2016 page 24" href="http://viewer.zmags.com/publication/2e5dba2c?page=24"> crossover, survival probability diverged, showing</a>
<a title="European Medical Journal 1.2 2016 page 25" href="http://viewer.zmags.com/publication/2e5dba2c?page=25"> colorectal cancer: analysis of the CORREC</a>
<a title="European Medical Journal 1.2 2016 page 26" href="http://viewer.zmags.com/publication/2e5dba2c?page=26"> EDITOR’S PICK In t</a>
<a title="European Medical Journal 1.2 2016 page 27" href="http://viewer.zmags.com/publication/2e5dba2c?page=27"> simplicity and a lower risk of bleeding. T</a>
<a title="European Medical Journal 1.2 2016 page 28" href="http://viewer.zmags.com/publication/2e5dba2c?page=28"> in UF after three sessions were identified </a>
<a title="European Medical Journal 1.2 2016 page 29" href="http://viewer.zmags.com/publication/2e5dba2c?page=29"> AKI + need for RRT </a>
<a title="European Medical Journal 1.2 2016 page 30" href="http://viewer.zmags.com/publication/2e5dba2c?page=30"> George et al.30 performed a randomised study to c</a>
<a title="European Medical Journal 1.2 2016 page 31" href="http://viewer.zmags.com/publication/2e5dba2c?page=31"> patient groups with no comorbidities, while other</a>
<a title="European Medical Journal 1.2 2016 page 32" href="http://viewer.zmags.com/publication/2e5dba2c?page=32"> penetration rate among incident patients starting</a>
<a title="European Medical Journal 1.2 2016 page 33" href="http://viewer.zmags.com/publication/2e5dba2c?page=33"> Urologic, & Hematologic Diseases. United States R</a>
<a title="European Medical Journal 1.2 2016 page 34" href="http://viewer.zmags.com/publication/2e5dba2c?page=34"> PATIENT INSIGHT AND TREATMENT EXPECTATION</a>
<a title="European Medical Journal 1.2 2016 page 35" href="http://viewer.zmags.com/publication/2e5dba2c?page=35"> The aim was to collect data via recruitment of se</a>
<a title="European Medical Journal 1.2 2016 page 36" href="http://viewer.zmags.com/publication/2e5dba2c?page=36"> 70 61 Male Female 6052 Respondents (%) 50 40 </a>
<a title="European Medical Journal 1.2 2016 page 37" href="http://viewer.zmags.com/publication/2e5dba2c?page=37"> Respondents percentage 0.0 10.0 </a>
<a title="European Medical Journal 1.2 2016 page 38" href="http://viewer.zmags.com/publication/2e5dba2c?page=38"> first three compounds.42 Avanafil has a more rapid </a>
<a title="European Medical Journal 1.2 2016 page 39" href="http://viewer.zmags.com/publication/2e5dba2c?page=39"> 36 Average per-patient successful sexual attempt</a>
<a title="European Medical Journal 1.2 2016 page 40" href="http://viewer.zmags.com/publication/2e5dba2c?page=40"> concerns regarding the preservation of spontaneit</a>
<a title="European Medical Journal 1.2 2016 page 41" href="http://viewer.zmags.com/publication/2e5dba2c?page=41"> 32. Debruyne FM et al. Time to onset of action of</a>
<a title="European Medical Journal 1.2 2016 page 42" href="http://viewer.zmags.com/publication/2e5dba2c?page=42"> EMJ EUROPEAN MEDICAL </a>
<a title="European Medical Journal 1.2 2016 page 43" href="http://viewer.zmags.com/publication/2e5dba2c?page=43"> THE MULTIFACTORIAL BACKGROUND OF EMERGING VIR</a>
<a title="European Medical Journal 1.2 2016 page 44" href="http://viewer.zmags.com/publication/2e5dba2c?page=44"> to this dilemma, as it is common to assume that s</a>
<a title="European Medical Journal 1.2 2016 page 45" href="http://viewer.zmags.com/publication/2e5dba2c?page=45"> exceptionally high levels of viraemia for several</a>
<a title="European Medical Journal 1.2 2016 page 46" href="http://viewer.zmags.com/publication/2e5dba2c?page=46"> led to ZIKV spread to countries in Central, North</a>
<a title="European Medical Journal 1.2 2016 page 47" href="http://viewer.zmags.com/publication/2e5dba2c?page=47"> As the majority of neurological disease cases are</a>
<a title="European Medical Journal 1.2 2016 page 48" href="http://viewer.zmags.com/publication/2e5dba2c?page=48"> REFERENCES 1. Morse SS et al. Prediction and pre</a>
<a title="European Medical Journal 1.2 2016 page 49" href="http://viewer.zmags.com/publication/2e5dba2c?page=49"> Lancet Infect Dis. 2016;16:278-9. 51. Musso D </a>
<a title="European Medical Journal 1.2 2016 page 50" href="http://viewer.zmags.com/publication/2e5dba2c?page=50"> NEXT GENERATION SEQUENCING: A </a>
<a title="European Medical Journal 1.2 2016 page 51" href="http://viewer.zmags.com/publication/2e5dba2c?page=51"> Patient sample Next generation sequencing Valid</a>
<a title="European Medical Journal 1.2 2016 page 52" href="http://viewer.zmags.com/publication/2e5dba2c?page=52"> Table 1: Sequencing platforms and characteristics</a>
<a title="European Medical Journal 1.2 2016 page 53" href="http://viewer.zmags.com/publication/2e5dba2c?page=53"> manifest in early childhood; which is phenotypica</a>
<a title="European Medical Journal 1.2 2016 page 54" href="http://viewer.zmags.com/publication/2e5dba2c?page=54"> transcriptome sequencing of microRNA (miRNA) with</a>
<a title="European Medical Journal 1.2 2016 page 55" href="http://viewer.zmags.com/publication/2e5dba2c?page=55"> cfDNA was highly associated with acute rejection </a>
<a title="European Medical Journal 1.2 2016 page 56" href="http://viewer.zmags.com/publication/2e5dba2c?page=56"> REFERENCES 1. Sanger F et al. DNA sequencing wit</a>
<a title="European Medical Journal 1.2 2016 page 57" href="http://viewer.zmags.com/publication/2e5dba2c?page=57"> analysis by next generation sequencing allows com</a>
<a title="European Medical Journal 1.2 2016 page 58" href="http://viewer.zmags.com/publication/2e5dba2c?page=58"> THE ROLE OF GENDER IN CHRONIC KIDNEY DISEASE </a>
<a title="European Medical Journal 1.2 2016 page 59" href="http://viewer.zmags.com/publication/2e5dba2c?page=59"> 2012 was higher in women (15.1%) than in men (12.</a>
<a title="European Medical Journal 1.2 2016 page 60" href="http://viewer.zmags.com/publication/2e5dba2c?page=60"> In a study which used the gold standard method fo</a>
<a title="European Medical Journal 1.2 2016 page 61" href="http://viewer.zmags.com/publication/2e5dba2c?page=61"> GENDER ASPECTS REGARDING MORTALITY Several stud</a>
<a title="European Medical Journal 1.2 2016 page 62" href="http://viewer.zmags.com/publication/2e5dba2c?page=62"> (playing an important role in the developme</a>
<a title="European Medical Journal 1.2 2016 page 63" href="http://viewer.zmags.com/publication/2e5dba2c?page=63"> It seems that the influence of sex hormones on sev</a>
<a title="European Medical Journal 1.2 2016 page 64" href="http://viewer.zmags.com/publication/2e5dba2c?page=64"> kidney disease: a longitudinal study. Am J Kidney</a>
<a title="European Medical Journal 1.2 2016 page 65" href="http://viewer.zmags.com/publication/2e5dba2c?page=65"> CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN </a>
<a title="European Medical Journal 1.2 2016 page 66" href="http://viewer.zmags.com/publication/2e5dba2c?page=66"> the risk of COPD, and may do so independently of,</a>
<a title="European Medical Journal 1.2 2016 page 67" href="http://viewer.zmags.com/publication/2e5dba2c?page=67"> Table 1: Characteristics of the examined groups. </a>
<a title="European Medical Journal 1.2 2016 page 68" href="http://viewer.zmags.com/publication/2e5dba2c?page=68"> were significantly lower in welders. The mea</a>
<a title="European Medical Journal 1.2 2016 page 69" href="http://viewer.zmags.com/publication/2e5dba2c?page=69"> Table 3: Mean baseline and post-bronchodilator va</a>
<a title="European Medical Journal 1.2 2016 page 70" href="http://viewer.zmags.com/publication/2e5dba2c?page=70"> number of the subjects in the study groups could </a>
<a title="European Medical Journal 1.2 2016 page 71" href="http://viewer.zmags.com/publication/2e5dba2c?page=71"> THE RISE AND FALL OF ROUTINE MANUAL THROMBEC</a>
<a title="European Medical Journal 1.2 2016 page 72" href="http://viewer.zmags.com/publication/2e5dba2c?page=72"> echocardiography at 6 months in the MT group. The</a>
<a title="European Medical Journal 1.2 2016 page 73" href="http://viewer.zmags.com/publication/2e5dba2c?page=73"> the translation of the mechanical removal o</a>
<a title="European Medical Journal 1.2 2016 page 74" href="http://viewer.zmags.com/publication/2e5dba2c?page=74"> in-hospital MACE. The median follow-up duration w</a>
<a title="European Medical Journal 1.2 2016 page 75" href="http://viewer.zmags.com/publication/2e5dba2c?page=75"> Randomized Trials. Circ Cardiovasc Interv. 2015;8</a>
<a title="European Medical Journal 1.2 2016 page 76" href="http://viewer.zmags.com/publication/2e5dba2c?page=76"> TREATMENT OPPORTUNITIES FOR COLORECTAL LIVER META</a>
<a title="European Medical Journal 1.2 2016 page 77" href="http://viewer.zmags.com/publication/2e5dba2c?page=77"> cancer, a pooled analysis revealed that two-third</a>
<a title="European Medical Journal 1.2 2016 page 78" href="http://viewer.zmags.com/publication/2e5dba2c?page=78"> example, given their reliance on angiogenesi</a>
<a title="European Medical Journal 1.2 2016 page 79" href="http://viewer.zmags.com/publication/2e5dba2c?page=79"> Essentially, genetic and epigenetic alter</a>
<a title="European Medical Journal 1.2 2016 page 80" href="http://viewer.zmags.com/publication/2e5dba2c?page=80"> cases rendering the CLM unresectable. This is a p</a>
<a title="European Medical Journal 1.2 2016 page 81" href="http://viewer.zmags.com/publication/2e5dba2c?page=81"> A computed tomography scan is performed</a>
<a title="European Medical Journal 1.2 2016 page 82" href="http://viewer.zmags.com/publication/2e5dba2c?page=82"> REFERENCES 1. Ferlay J et al. Cancer incidence a</a>
<a title="European Medical Journal 1.2 2016 page 83" href="http://viewer.zmags.com/publication/2e5dba2c?page=83"> agonists: Multi-potent potentatiors of Tumor I</a>
<a title="European Medical Journal 1.2 2016 page 84" href="http://viewer.zmags.com/publication/2e5dba2c?page=84"> SUBSCRIBE Follow us: FREE TO OUR YOUTUBE CHA</a>
<a title="European Medical Journal 1.2 2016 page 85" href="http://viewer.zmags.com/publication/2e5dba2c?page=85"> ALCOHOLIC LIVER DISEASE: A COMPREHENSIVE REVIEW </a>
<a title="European Medical Journal 1.2 2016 page 86" href="http://viewer.zmags.com/publication/2e5dba2c?page=86"> obesity,10 genetic polymorphisms,11 and c</a>
<a title="European Medical Journal 1.2 2016 page 87" href="http://viewer.zmags.com/publication/2e5dba2c?page=87"> Table 1: Alcohol content in different beverages. </a>
<a title="European Medical Journal 1.2 2016 page 88" href="http://viewer.zmags.com/publication/2e5dba2c?page=88"> Therapeutic algorithm for management of alcoholic</a>
<a title="European Medical Journal 1.2 2016 page 89" href="http://viewer.zmags.com/publication/2e5dba2c?page=89"> (based on serum bilirubin, albumin, PT, hep</a>
<a title="European Medical Journal 1.2 2016 page 90" href="http://viewer.zmags.com/publication/2e5dba2c?page=90"> and obesity are poor outcome predictors in liver </a>
<a title="European Medical Journal 1.2 2016 page 91" href="http://viewer.zmags.com/publication/2e5dba2c?page=91"> THERAPY FOR ALCOHOLIC CIRRHOSIS None of the exis</a>
<a title="European Medical Journal 1.2 2016 page 92" href="http://viewer.zmags.com/publication/2e5dba2c?page=92"> Clin Liver Dis. 2012;16(4):763-81. 24. Hock B et </a>
<a title="European Medical Journal 1.2 2016 page 93" href="http://viewer.zmags.com/publication/2e5dba2c?page=93"> NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): </a>
<a title="European Medical Journal 1.2 2016 page 94" href="http://viewer.zmags.com/publication/2e5dba2c?page=94"> mortality was 1.038 and 9.32, respectively.12 The</a>
<a title="European Medical Journal 1.2 2016 page 95" href="http://viewer.zmags.com/publication/2e5dba2c?page=95"> liver enzymes and other measurable outcomes has b</a>
<a title="European Medical Journal 1.2 2016 page 96" href="http://viewer.zmags.com/publication/2e5dba2c?page=96"> associated with improvements in all major NASH ac</a>
<a title="European Medical Journal 1.2 2016 page 97" href="http://viewer.zmags.com/publication/2e5dba2c?page=97"> not reach statistical significance. Compared with </a>
<a title="European Medical Journal 1.2 2016 page 98" href="http://viewer.zmags.com/publication/2e5dba2c?page=98"> Table 1: Novel therapeutic agents aiming at key m</a>
<a title="European Medical Journal 1.2 2016 page 99" href="http://viewer.zmags.com/publication/2e5dba2c?page=99"> 375-8. 16. Matteoni CA et al. Nonalcoholic fatty </a>
<a title="European Medical Journal 1.2 2016 page 100" href="http://viewer.zmags.com/publication/2e5dba2c?page=100"> systematic review and meta-analysis. Clin Gast</a>
<a title="European Medical Journal 1.2 2016 page 101" href="http://viewer.zmags.com/publication/2e5dba2c?page=101"> PRIMARY PARAGANGLIOMA OF THE THYROID GLAND: C</a>
<a title="European Medical Journal 1.2 2016 page 102" href="http://viewer.zmags.com/publication/2e5dba2c?page=102"> The right lobe was unremarkable. The patient’s vi</a>
<a title="European Medical Journal 1.2 2016 page 103" href="http://viewer.zmags.com/publication/2e5dba2c?page=103"> Figure 2: Thyroid tissue infiltrated by a tumour t</a>
<a title="European Medical Journal 1.2 2016 page 104" href="http://viewer.zmags.com/publication/2e5dba2c?page=104"> paragangliomas.14 What makes the diagnosis more </a>
<a title="European Medical Journal 1.2 2016 page 105" href="http://viewer.zmags.com/publication/2e5dba2c?page=105"> Table 1 continued. Author Sex Age (Years) </a>
<a title="European Medical Journal 1.2 2016 page 106" href="http://viewer.zmags.com/publication/2e5dba2c?page=106"> thyroglobulin and TTF1. However, like paraganglio</a>
<a title="European Medical Journal 1.2 2016 page 107" href="http://viewer.zmags.com/publication/2e5dba2c?page=107"> EUROPEAN MEDICAL JOURNAL provides influential arti</a>
<a title="European Medical Journal 1.2 2016 page 108" href="http://viewer.zmags.com/publication/2e5dba2c?page=108"> OUTCOMES OF SALVAGE LYMPH NODE DISSECTION FOR </a>
<a title="European Medical Journal 1.2 2016 page 109" href="http://viewer.zmags.com/publication/2e5dba2c?page=109"> HRT in patients with disease relapse limited to l</a>
<a title="European Medical Journal 1.2 2016 page 110" href="http://viewer.zmags.com/publication/2e5dba2c?page=110"> median of three positive nodes on final histology </a>
<a title="European Medical Journal 1.2 2016 page 111" href="http://viewer.zmags.com/publication/2e5dba2c?page=111"> Table 1 continued. Variable All patients (N=1</a>
<a title="European Medical Journal 1.2 2016 page 112" href="http://viewer.zmags.com/publication/2e5dba2c?page=112"> referred to HRT,5 being at increased risk of deat</a>
<a title="European Medical Journal 1.2 2016 page 113" href="http://viewer.zmags.com/publication/2e5dba2c?page=113"> Table 2 continued. Variable All patients (N=1</a>
<a title="European Medical Journal 1.2 2016 page 114" href="http://viewer.zmags.com/publication/2e5dba2c?page=114"> The outcomes of our multi-institutional report ar</a>
<a title="European Medical Journal 1.2 2016 page 115" href="http://viewer.zmags.com/publication/2e5dba2c?page=115"> REFERENCES 1. Heidenreich A et al. EAU guideline</a>
<a title="European Medical Journal 1.2 2016 page 116" href="http://viewer.zmags.com/publication/2e5dba2c?page=116"> ADVERTORIAL GI CONNECT: AN INTERNATIONAL INITIATI</a>
<a title="European Medical Journal 1.2 2016 page 117" href="http://viewer.zmags.com/publication/2e5dba2c?page=117"> ADVERTORIAL The level of expertise and </a>
<a title="European Medical Journal 1.2 2016 page 118" href="http://viewer.zmags.com/publication/2e5dba2c?page=118"> SUBSCRIBE TO RECEIVE THE LATEST PUBLICATIONS, NE</a>